Company: PCRX
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001396814-25-000061
Chunk: 151

Company: Pacira BioSciences, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 8
Chunk 151
---
, all available-for-sale investments had an “A” or better rating by Standard & Poor’s. 

Pacira BioSciences, Inc.  |  Q1 2025 Form 10-Q  |  Page 23

The following summarizes the Company’s short-term available-for-sale investments at March 31, 2025 and December 31, 2024 (in thousands): March 31, 2025 InvestmentsCostGrossUnrealizedGainsGrossUnrealizedLossesFair Value(Level 2)Current:Asset-backed securities$10,691 $10 $(2)$10,699 Commercial paper154,105 42 (30)154,117 Corporate bonds40,179 11 (6)40,184 Yankee bond5,006 10 — 5,016           Total$209,981 $73 $(38)$210,016 December 31, 2024 InvestmentsCostGrossUnrealizedGainsGrossUnrealizedLossesFair Value(Level 2)Current:Asset-backed securities$21,626 $43 $— $21,669 Commercial paper142,556 120 (55)142,621 Corporate bonds32,502 25 (5)32,522 U.S. federal agency bonds5,996 8 — 6,004 Yankee bond5,012 13 — 5,025           Total$207,692 $209 $(60)$207,841 At March 31, 2025, there were no investments available for sale that were materially less than their amortized cost.The Company elects to recognize its interest receivable separate from its available-for-sale investments. At March 31, 2025 and December 31, 2024, the interest receivable from its available-for-sale investments recognized in prepaid expenses and other current assets was $0.4 million and $0.5 million, respectively.Credit RiskFinancial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, short-term and long-term available-for-sale investments and accounts receivable. The Company maintains its cash and cash equivalents with high-credit quality financial institutions. Such amounts may exceed federally-insured limits. As of March 31, 2025, three wholesalers each accounted for over 10% of the Company’s accounts receivable,